Opthea Ltd at ASX Small and Mid-Cap Conference (Virtual) Transcript
Thanks very much for the opportunity to present at this conference. It's a pleasure to be here. And thanks, everyone, for tuning in.
We are a retinal eye disease company. We're developing a novel therapy for the treatment of the leading cause of blindness in the elderly population, which is wet age-related macular degeneration. And it's a pleasure to be able to tell you a little bit about our development program, which is right now in the last and final stage of clinical development, which is Phase 3 clinical trials for the treatment of wet AMD.
This is the requisite disclaimer regarding forward-looking statements. So let me tell you a little bit of a snapshot, a little bit about OPT-302, which is our lead clinical development candidate for the treatment of wet AMD. This molecule is a first-in-class VEGF-C/D trap inhibitor. It's essentially a therapy for the treatment of wet AMD that is to be used in combination with the current approved standard of care treatments for this disease, in order to produce better visual acuity outcomes for patients
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
